News

News and Press Releases
Coronavirus (COVID-19) | Care Centers Over 10,000 Home Spirometers Provided for Virtual Care Visits Through CF Foundation Program

The Cystic Fibrosis Foundation has arranged for over 10,000 home spirometers to be provided to care centers to support continued access to high quality, comprehensive care during the COVID-19 pandemic.

| 2 min read
Research | About the CF Foundation | Our Research Approach CF Foundation Awards Nearly $15 Million to Spur Infection Research

Thirty-three new projects are being funded as part of the Foundation's $100 million Infection Research Initiative.

| 4 min read
Drug Pipeline Positive Phase 3 Results of Trikafta Provide Further Evidence of Efficacy

Today, Vertex Pharmaceuticals Inc. announced positive Phase 3 study results for Trikafta® (elexacaftor/tezacaftor/ivacaftor) for people with cystic fibrosis ages 12 years and older who have one copy of the F508del mutation and one gating or residual function mutation.

| 2 min read
Get Involved | About the CF Foundation CF Foundation Announces 2020 Impact Grant Recipients

Recipients include four programs from around the country that engage and empower the CF community.

| 4 min read
Our Research Approach CF Foundation Leadership Represents the CF Community Voice During Global Antibiotics Initiative Launch

On July 9, the Cystic Fibrosis Foundation's President and CEO, Dr. Michael P. Boyle, participated in the global launch of the AMR Action Fund. Alongside leaders in global health, Dr. Boyle highlighted the critical need of antibiotics for people living with CF and stressed that research investment alone will not solve the challenges of antibiotic development.

| 3 min read
Advocacy | Our Advocacy Work Nearly 200 Teens Gather Virtually for the Foundation’s 12th Annual Teen Advocacy Day

Nearly 200 teens from across the country -- nearly half living with cystic fibrosis -- participated in the Foundation's Virtual Teen Advocacy Day to advocate for the CF community.

| 3 min read
Research | Antibiotics | Our Research Approach CF Foundation Awards Up to $5.6 Million to Develop Novel Antibiotic to Fight Drug-Resistant Bacteria

The Cystic Fibrosis Foundation has awarded up to $5.6 million to Microbion Corporation to develop a novel, inhaled antibiotic to treat drug-resistant bacterial infections in people with cystic fibrosis.

| 2 min read
Research | Clinical Trials | Our Research Approach CF Foundation Awards Funding for First-Ever Controlled Clinical Study of Phage Therapy in CF

The Cystic Fibrosis Foundation awarded up to $5 million to Armata Pharmaceuticals for the first-ever controlled clinical study of phage therapy in CF, reaffirming the Foundation's commitment to advance innovative solutions to the growing challenge of antibiotic resistance.

| 3 min read
Advocacy | Our Advocacy Work More than 200 Advocates Urge Congress for More Antibiotics During March on the Hill

More than 200 advocates gathered on Capitol Hill during the Cystic Fibrosis Foundation's 14th Annual March on the Hill, championing antibiotic research and development and other policy needs on behalf of people with CF.

| 3 min read
CFTR Modulators ICER Issues Draft Evidence Report for Assessment of Trikafta

The Institute for Clinical and Economic Review (ICER) recently posted a draft evidence report to outline their initial assessment of the clinical effectiveness and value of CFTR modulators, including elexacaftor/tezacaftor/ivacaftor (TrikaftaTM). The document is open for public comment through March 18.

 

| 2 min read